CLINICAL TRIALS Clinical trials built around real lives and experiences
Clinical trials give patients the opportunity to play an active role in advancing new treatments. At Minerva, we design our studies with that responsibility in mind, recognizing the daily burden many people living with schizophrenia already carry.
CLINICAL TRIALS
Our investigational monotherapy, roluperidone, has the potential to improve negative symptoms such as lack of motivation, engagement, and social connection, which are often overlooked in traditional schizophrenia studies. Roluperidone has been extensively studied in Phase 2b and Phase 3 clinical trials.
From study design to endpoint selection, we prioritize approaches that attempt to reduce patient burden while capturing changes that patients can truly feel. We believe clinical research should not only advance science, but also respect the experience of those who make it possible.
ACTIVE CLINICAL TRIALS
Phase 3 confirmatory trial: A double-blind study investigating roluperidone for the treatment of negative symptoms in schizophrenia (NCT07565428)